ISPOR LATIN AMERICA CONSORTIUM PUBLISHES FIRST SCIENCE POLICY BRIEF

Published Jan 12, 2016

“BUDGET IMPACT ANALYSIS: NEW NORMS”

 Princeton, NJ—January 12, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today that its Latin America Consortium Publications Committee has published its first Science Policy Brief—Budget Impact Analysis: New Norms (El Análisis del Impacto Presupuestario: Nuevas Normas). This Science Policy Brief is based on the guidance recommendations from the ISPOR Task Force Report, “Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force,” published in Value in Health [2014 Jan-Feb;17(1):5-14]. The Latin America Consortium Science Policy Brief—Budget Impact Analysis: New Norms—is published in Spanish, Portuguese, and English. This new Science Policy Brief explores the issue of budget impact analyses (BIAs), which are an essential part of assessing affordability of health care interventions and are increasingly required by reimbursement authorities. This Brief, and the original Task Force Report, present updated guidance on methods for undertaking BIAs. For example, recommendations on new intervention BIA design should take into account: (1) relevant features of the health care system, (2) possible access restrictions, (3) the anticipated update of the new intervention, and (4) the use and effects of the current and new interventions. ISPOR Science Policy Briefs are designed to communicate consensus guidance recommendations of ISPOR Good Practices for Outcomes Research Reports in a format that is easily accessible and especially relevant for public and private stakeholders who have non-technical backgrounds. All of the Good Practices for Outcomes Research Reports may be found here. Additional information on the Latin America Consortium may be found here.

###

Related Stories

Landmark Analysis in Value in Health Uncovers Potential Research Efficiency Gains

Sep 15, 2025

Value in Health, the official journal of ISPOR announced the publication of a landmark scoping review that provides a comprehensive mapping of patient preference studies across key medical domains, revealing the first robust evidence base for advancing meta-analyses and benefit transfer methods in healthcare decision-making.

ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Sep 9, 2025

ISPOR announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

"Most-Favored Nation" Drug Pricing Strategy May Backfire, New Research Warns

Sep 3, 2025

Value in Health, the official journal of ISPOR announced the publication of a new analysis suggesting that the Trump Administration's "Most-Favored Nation" approach to lowering US drug prices by referencing international prices may not achieve its intended goals, based on decades of experience with similar policies in Europe.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×